Ranibizumab biosimilar - Sun Pharmaceutical Industries
Latest Information Update: 08 Dec 2020
At a glance
- Originator Sun Pharmaceutical Industries
- Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Wet age-related macular degeneration
Most Recent Events
- 23 Oct 2020 Sun Pharmaceutical Industries plans a phase III trial for Wet age-related macular degeneration in India (CTRI2020-09-027629 )
- 07 Sep 2020 Preclinical trials in Wet age-related macular degeneration in India (Intravitreous) before September 2020